Allogene Therapeutics, Inc. (Nasdaq: ALLO), clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for cancer, visited the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO).
Allogene Therapeutics, Inc. (Nasdaq: ALLO), clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for cancer, visited the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO).